TNBC is regrettably excluded from the effective targeted therapy used in luminal and HER2-positive breast carcinomas due to its lack of hormonal and Human Epidermal Growth Factor receptor expression [20,24–28]. The gene discussed is ERBB2; the disease is breast carcinoma.